Krishna Rao, MD
Infectious Disease · Ann Arbor, MINPI 1538384219
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,250 of the $3,287 with a category attached, or 98.9%. Aimmune Therapeutics, Inc. accounts for 98.9% of it on its own, with 1 other manufacturer making up the rest.
Across 3 payments — averaging $1095.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aimmune Therapeutics, Inc.$3K
- Merck$37
Across 5 payments — averaging $81,310 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$407K
What the payments were for
- Speaking & faculty fees$3,25099%
- Education$371%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aimmune Therapeutics, Inc. | 1 | $3,250 |
| Merck | 2 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOWST$3,250
How this compares
$3,287 in reported general payments places this provider in the 85th percentile of 257 infectious disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StribildElviteg/Cob/Emtri/Tenofo Disop | 11 | $45,202 |
| ErtapenemErtapenem Sodium | 13 | $3,918 |
| Daptomycin | 11 | $3,721 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 20 | $367 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Ann Arbor
- Keith KayeAnn Arbor$187K
- Owen AlbinAnn Arbor$25K
- David MarkovitzAnn Arbor$24K
- Payal PatelAnn Arbor$23K
- Marisa MiceliAnn Arbor$19K
- Adam LauringAnn Arbor$7K
- Laraine WasherAnn Arbor$3K
- Suzanne BradleyAnn Arbor$2K
- Peter GulickLansing$850K
- Teena ChopraDetroit$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.